# Risankizumab Long-term Remission Study

> **NCT04630652** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Jaehwan Kim** · enrollment: 20 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Risankizumab-Rzaa
- **PROCEDURE:** Punch biopsies of the skin at baseline visit
- **PROCEDURE:** Punch biopsies of the skin at week 28 visit

## Key facts

- **NCT ID:** NCT04630652
- **Lead sponsor:** Jaehwan Kim
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-07
- **Primary completion:** 2026-02-28
- **Final completion:** 2027-07-28
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-11-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04630652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04630652, "Risankizumab Long-term Remission Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04630652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*